ACOR.Q Stock Overview
A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Acorda Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$18.21 |
| 52 Week Low | US$0.25 |
| Beta | 1.65 |
| 1 Month Change | -61.54% |
| 3 Month Change | -97.65% |
| 1 Year Change | -97.01% |
| 3 Year Change | -99.61% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?
Feb 21
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement
Dec 18Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?
Jun 05Acorda wins $16.5M in Ampyra arbitration case with Alkermes
Oct 17Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote
Oct 10Acorda inks license deal with Asieris for pre-clinical drug
Aug 29Acorda Therapeutics announces resignation of COO
Aug 19Acorda Therapeutics: Managing The Transition
Oct 04Acorda Therapeutics Continues To Maneuver For A Turnaround
Jul 24CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action
Jun 17Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now
May 26Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts
Mar 09Acorda Therapeutics to sell Inbrija manufacturing operations for $80M, reduces headcount by 16%, shares up 65%
Jan 13What Kind Of Investors Own Most Of Acorda Therapeutics, Inc. (NASDAQ:ACOR)?
Jan 04Acorda Therapeutics completes 1-for-6 reverse stock split
Dec 31Acorda Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 05Shareholder Returns
| ACOR.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -24.1% | 4.2% | 1.8% |
| 1Y | -97.0% | 8.1% | 22.8% |
Return vs Industry: ACOR.Q underperformed the US Biotechs industry which returned 8.1% over the past year.
Return vs Market: ACOR.Q underperformed the US Market which returned 22.8% over the past year.
Price Volatility
| ACOR.Q volatility | |
|---|---|
| ACOR.Q Average Weekly Movement | 42.9% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ACOR.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ACOR.Q's weekly volatility has increased from 24% to 43% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 102 | Ron Cohen | www.acorda.com |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.
Acorda Therapeutics, Inc. Fundamentals Summary
| ACOR.Q fundamental statistics | |
|---|---|
| Market cap | US$360.21k |
| Earnings (TTM) | -US$263.42m |
| Revenue (TTM) | US$115.66m |
0.0x
P/S Ratio0.0x
P/E RatioIs ACOR.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACOR.Q income statement (TTM) | |
|---|---|
| Revenue | US$115.66m |
| Cost of Revenue | US$20.48m |
| Gross Profit | US$95.19m |
| Other Expenses | US$358.61m |
| Earnings | -US$263.42m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -212.08 |
| Gross Margin | 82.30% |
| Net Profit Margin | -227.75% |
| Debt/Equity Ratio | -103.1% |
How did ACOR.Q perform over the long term?
See historical performance and comparison